Online citations, reference lists, and bibliographies.

Amorphous Drug Solubility And Absorption Enhancement

Marzena Rams-Baron, R. Jachowicz, E. Boldyreva, Deliang Zhou, Witold Jamróz, M. Paluch
Published 2018 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
The poor oral bioavailability of many active pharmaceutical ingredients (APIs) resulting from low solubility is one of the important challenges in pharmaceutical technology. Over the last two decades the number of relatively insoluble drugs has grown steadily. Nowadays it is estimated that approximately 70% of new drug candidates are characterized by poor solubility. In order to ensure the optimum therapeutic efficacy, the selection of the drug substance and formulation is crucial in drug design. The development and approval of new, innovative and safe drugs is tremendously complex and requires extensive knowledge of materials, current technological processes and regulations. Bearing in mind that the form of drug should be suitable for the administration route and safe to apply, understanding of manufacturing process is of key importance to successful dosage form development.
This paper references
10.1023/A:1007516718048
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Bruno C. Hancock (2004)
10.1016/j.ijpharm.2011.08.032
Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Y. Kawabata (2011)
10.1016/J.DRUDIS.2007.09.005
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
Teófilo Vasconcelos (2007)
10.1016/S0169-409X(96)00423-1
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C. Lipinski (1997)
10.1016/j.ijpharm.2012.12.020
Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process.
J. Park (2013)
10.1002/JPS.20806
Hot-melt extrusion for enhanced delivery of drug particles.
D. Miller (2007)
10.1016/j.ijpharm.2017.02.062
Amorphous is not always better-A dissolution study on solid state forms of carbamazepine.
Linda G. Jensen (2017)
10.1016/j.xphs.2015.10.008
Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
S. Baghel (2016)
10.1016/j.ijpharm.2016.08.009
Unexpected solvent impact in the crystallinity of praziquantel/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study.
Emanuel D. Costa (2016)
10.1023/A:1022652004114
The Mean Dissolution Time Depends on the Dose/Solubility Ratio
E. Rinaki (2004)
10.1016/j.ddtec.2012.03.006
Optimizing the physical form - opportunities and limitations.
S. Byrn (2012)
10.1016/S0378-5173(01)00741-4
In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions.
N. Zerrouk (2001)
10.1007/s11095-013-1178-1
Correlation of Inhibitory Effects of Polymers on Indomethacin Precipitation in Solution and Amorphous Solid Crystallization Based on Molecular Interaction
Harsh Raj Chauhan (2013)
10.1016/j.ijpharm.2016.05.002
Poloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailability.
Chung Kil Song (2016)
10.1016/S0378-5173(01)00891-2
The mechanisms of drug release from solid dispersions in water-soluble polymers.
D. Craig (2002)
10.1016/j.ejpb.2016.05.017
Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions.
Matthias Manne Knopp (2016)
10.1080/03639040500529176
Supersaturation Produces High Bioavailability of Amorphous Danazol Particles Formed by Evaporative Precipitation into Aqueous Solution and Spray Freezing into Liquid Technologies
J. M. Vaughn (2006)
10.1016/j.ejpb.2016.11.023
Dissolution behavior of co‐amorphous amino acid‐indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin
Rami Ojarinta (2017)
10.1016/j.ijpharm.2011.04.006
Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique.
Songming Li (2011)
10.1016/j.addr.2016.01.012
Amorphous solid dispersions: Rational selection of a manufacturing process.
Teófilo Vasconcelos (2016)
10.1016/j.ejpb.2013.10.005
Supersaturation, nucleation, and crystal growth during single- and biphasic dissolution of amorphous solid dispersions: polymer effects and implications for oral bioavailability enhancement of poorly water soluble drugs.
Ashish L. Sarode (2014)
PHYSICOCHEMICAL CHARACTERIZATION OF SPRAY DRIED FORMULATION CONTAINING AMORPHOUS DRUG
Glorybel L Pastrano (2012)
10.1016/j.ejpb.2012.09.016
Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.
J. Moes (2013)
10.1016/j.ijpharm.2015.09.069
Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Ritesh Fule (2015)
10.1016/j.ijpharm.2012.10.041
Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches).
David Paul Elder (2013)
10.1016/j.ijpharm.2016.11.005
Oral hesperidin-Amorphization and improved dissolution properties by controlled loading onto porous silica.
Q. Wei (2017)
10.1016/J.POLYMER.2015.09.026
The role of polymers in oral bioavailability enhancement; a review
Haoyu Liu (2015)
10.1007/s11095-015-1823-y
Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations
Tian Xie (2015)
10.1016/j.ejps.2014.05.026
The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil.
Krzysztof Wlodarski (2014)
10.1016/j.ejpb.2013.09.007
Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs.
Chau Le-Ngoc Vo (2013)
10.1016/J.JDDST.2016.06.004
Dissolution enhancement of the poorly soluble drug nifedipine by co-spray drying with microporous zeolite beta
Christina Karavasili (2016)
10.1016/J.JCONREL.2004.03.018
Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions.
D. V. van Drooge (2004)
10.1016/j.ijpharm.2013.05.061
Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
C. Brough (2013)
10.1021/mp800042d
Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
James C Dinunzio (2008)
10.1016/J.IJPHARM.2003.07.010
Establishment of new preparation method for solid dispersion formulation of tacrolimus.
K. Yamashita (2003)
10.1007/s11095-009-0021-1
Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution
David E. Alonzo (2009)
10.1016/J.IJPHARM.2007.05.031
Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188.
Madhuri Newa (2007)
10.1080/03639040601050213
Part I: Characterization of Solid Dispersions of Nimodipine Prepared by Hot-melt Extrusion
X. Zheng (2007)
10.1016/j.ejps.2015.02.003
Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions.
Fan Meng (2015)
10.1002/jps.23374
Solvent-free melt electrospinning for preparation of fast dissolving drug delivery system and comparison with solvent-based electrospun and melt extruded systems.
Zsombor K. Nagy (2013)
10.1016/J.APSB.2013.06.007
Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion
Jia Liu (2013)
10.1002/jps.2600550508
Increasing Dissolution Rates and Gastrointestinal Absorption of Drugs via Solid Solutions and Eutectic mixtures III: Experimental Evaluation of Griseofulvin—succinic Acid Solid Solution
A. H. Goldberg (1966)
10.1016/j.ddtec.2011.10.002
The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate.
G. Mooter (2012)
10.1248/CPB.56.569
Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems.
Madhuri Newa (2008)
10.1016/j.carbpol.2015.04.071
Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion.
Rehmana Rashid (2015)
10.1023/A:1018907527253
Albendazole Generics—A Comparative In Vitro Study
E. Galia (2004)
10.1080/03639040601050205
Part II: Bioavailability in Beagle Dogs of Nimodipine Solid Dispersions Prepared by Hot-Melt Extrusion
X. Zheng (2007)
10.1248/cpb.9.866
Studies on Absorption of Eutectic Mixture. I. A Comparison of the Behavior of Eutectic Mixture of Sulfathiazole and that of Ordinary Sulfathiazole in Man.
K. Sekiguchi (1961)
10.1002/jps.21650
Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?
J. Brouwers (2009)
10.1080/03639040500214621
Characterization and Dissolution Properties of Ketoprofen in Binary and Ternary Solid Dispersions with Polyethylene Glycol and Surfactants
P. Mura (2005)
10.1016/j.ijpharm.2015.12.062
Hot melt extrusion based solid solution approach: Exploring polymer comparison, physicochemical characterization and in-vivo evaluation.
Ritesh Fule (2016)
10.1016/j.ijpharm.2010.08.007
Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
S. Onoue (2010)
10.1016/j.ejpb.2008.04.001
Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability.
R. Dhumal (2008)
10.1208/s12248-015-9825-6
Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating Formulations
Dajun D. Sun (2015)
10.1211/JPP.61.12.0001
Review: physical chemistry of solid dispersions
Sandrien Janssens (2009)
10.1016/S0169-409X(96)00487-5
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract
D. Hörter (1997)
10.1002/JPS.10566
Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.
D. Law (2004)
10.3109/03639045.2014.971027
Solubility and dissolution enhancement strategies: current understanding and recent trends*
S. Jain (2015)
10.3109/03639048009051934
Dissolution and Absorption of Nipedipine from Nifedipine-Polyvinylpyrrolidone Coprecipitate
Isao Sugimoto (1980)
Solid dispersion: A promising technique to enhance solubility of poorly water soluble drug
A. Sharma (2011)
10.1002/jps.22217
The developability classification system: application of biopharmaceutics concepts to formulation development.
J. Butler (2010)
10.1016/J.ADDR.2003.10.007
Impact of solid state properties on developability assessment of drug candidates.
L. Huang (2004)
10.1016/S0169-409X(00)00130-7
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract.
D. Hörter (2001)
10.1002/jps.2600600902
Pharmaceutical applications of solid dispersion systems.
W. Chiou (1971)
10.1016/J.ADDR.2007.05.009
Estimating drug solubility in the gastrointestinal tract.
J. Dressman (2007)
10.1016/j.ejpb.2016.12.031
Mucoadhesive amorphous solid dispersions for sustained release of poorly water soluble drugs
Justin S. Lafountaine (2017)
10.1016/j.ejpb.2012.09.019
Effect of amorphization method on telmisartan solubility and the tableting process.
P. Lepek (2013)
10.1016/j.xphs.2017.02.020
Effects of Temperature and Solvent on the Solid-State Transformations of Pranlukast During Mechanical Milling.
Xinnuo Xiong (2017)
10.1016/j.ejpb.2016.08.008
Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment.
M. Otsuka (2016)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)



Semantic Scholar Logo Some data provided by SemanticScholar